Scientific and Regulatory Basis for Development, Quality Assurance and Marketing Authorisation

Similar documents
QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS

QUALITY OF HERBAL REMEDIES

Guideline on quality of herbal medicinal products 1 /traditional herbal medicinal products

Guideline on quality of herbal medicinal products 2 /traditional herbal medicinal products

AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

H e r b a l M e dicines' Q U A L I T Y M ANUAL. I. Introduction

REPORT FROM THE AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS 1997/1998

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

Discussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012

Discussion at the HMPC January March Draft agreed by Quality Working Party April Adoption by CHMP for release for consultation 26 May 2005

Discussion by HMPC Drafting Group on Quality September Start of public consultation 15 February 2013

MEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA

Public Assessment Report Scientific discussion

Public Assessment Report Scientific discussion. Ginsana, soft capsule. Asp.no.:

Public Assessment Report Scientific discussion

Legal Requirements for the Control of Contaminants in Herbal Medicinal Products and Related Areas

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

Organisations and/or individuals

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

The European Union CD 1999/83/EEC on well-established use

Health Products Regulatory Authority IPAR. Public Assessment Report for a. Traditional Herbal Medicinal Product

Questions & answers on quality of herbal medicinal products/traditional herbal medicinal products 1

Draft agreed by HMPC Quality Drafting Group October Adopted by HMPC 12 November 2013

Particular challenges of evaluation of herbal combination products

European Union legislation on Food additives, Food enzymes, Extractions solvents and Food flavourings

European Medicines Agency Inspections

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON EQUISETUM ARVENSE L., HERBA

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

Public Assessment Report Scientific discussion. Ginsana, oral solution. Asp.no.:

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SOLIDAGO VIRGAUREA L., HERBA

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION OF COMMUNITY MONOGRAPHS FOR TRADITIONAL HERBAL MEDICINAL PRODUCTS

OVERVIEW OF COMMENTS RECEIVED ON COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM (EMEA/HMPC/114586/2008)

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG)

Fang-Chi Chang (M.D.,Ph.D.) Center for Drug Evaluation, Taiwan

General concepts in the Ph. Eur.: theory and rationale

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

Public Assessment Report Scientific discussion

European Medicines Agency COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Stability Testing of Herbal Medicinal Products

Public Assessment Report Scientific discussion

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

European Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

EDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines

Public Assessment Report Scientific discussion. Echinaforce Forte, tablet. Asp. No:

Good pharmacopoeial practices: Chapter on monographs on herbal medicines

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON PASSIFLORA INCARNATA L., HERBA

SCIENTIFIC DISCUSSION

DIRECTIVES. (Text with EEA relevance)

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam

Dormeasan, oral drops, solution (Valeriana officinalis L., radix, tincture; Humulus lupulus L., strobulus, tincture)

Decentralised Procedure. Public Assessment Report

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

GUIDANCE ON SUBMISSIONS FOR SAFETY EVALUATION OF SOURCES OF NUTRIENTS OR OF OTHER INGREDIENTS PROPOSED FOR USE IN THE MANUFACTURE OF FOODS

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX

Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope

Prof.Dr.Theodor Dingermann, Institut für Pharmazeutische Biologie, Goethe-Universität Frankfurt a.m.

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

Topics covered by the talk

Medicinal Products for Human Use HOMEOPATHIC MEDCINAL PRODUCT FOR HUMAN USE. December 2005

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

Opinion on the safety assessment of phospholipds obtained from egg yolk as food produced using a new process

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

Obstacles in Assessment and Licensing of Medicinal Products from Asian Traditional Medicines in Europe PD Dr. Werner Knöss BfArM

(Text with EEA relevance)

CHASTE TREE. Vitex agnus-castus L. (Lamiaceae) (McGuffin et al. 2000; USDA 1998) Source material(s): Fruit/Berry (Blumenthal 2000; Mills & Bone 2000)

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., HERBA

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

1 OJ L 354, , p OJ L 80, , p. 19.

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS

Expectations for Implementation in Europe

Excipient Risk Assessment

Formulation stability studies. 9.1 OBJECTIVE To monitor the stability of the developed herbal formulations using the limited and specific methods.

Meeting report, September 2005

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA OFFICINALIS L., RADIX

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON RUSCUS ACULEATUS L., RHIZOMA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

Public Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.

Public Assessment Report Scientific discussion

Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

Guide to Registration of Homeopathic Veterinary Medicinal Products

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Workshop for OIE national Focal Points for Veterinary Products November 2010, Johannesburg, South Africa. Presentation

Regulatory aspects of Herbal Medicinal Products. and Supplements in EU / the Netherlands. Ir. Theo van Rooij

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON BETULA PENDULA ROTH; BETULA PUBESCENS EHRH.

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

European Medicines Agency. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L.

Potential Grounds for Revocation of a Traditional Herbal Registration

Transcription:

Scientific and Regulatory Basis for Development, Quality Assurance and Marketing Authorisation Dr. Frauke Gaedcke, Waidesch Dr. Barbara Steinhoff, Konigswinter In collaboration with Dr. Helga Blasius, Remagen With 11 colour photographs, 37 black-and-white figures and 30 tables Scientific Publishers StUttgart 2003 CRC PRESS Boca Raton London New York Washington, DC.

Preface V Abbreviations.. XIII 1 Definitions 1 1.1 Phytotherapy 1 1.2 Herbal medicinal products 1 1.3 Herbal drugs 2 1.4 Herbal drug preparations 3 1.5 Herbal extracts 4 1.5.1 Classification of extracts in terms of their physical state 5 1.5.2 Native and not-native extracts (extract preparations) 6 1.5.3 Adjusted (standardised), quantified and "other" extracts 7 1.6 Preparations of fresh plants 7 1.7 Ratio of the herbal drug to the extraction solvent 8 1.8 Ratio of the herbal drug to the native herbal drug preparation (native extract) (DER native ) 9 1.8.1 Definition of the DER native 9 1.8.2 Calculation of the DER native 10 1.8.3 Calculation of the daily dose (DD) of the herbal drug preparation via the DER native 12 1.9 Ratio of the herbal drug to the herbal extract preparation 12 1.10 Factors influencing the quantity of native herbal drug preparation (native extract) and the DER native 13 1.11 What is meant by standardisation? 15 1.11.1 Measures designed to ensure consistency of a herbal extract 15 1.11.2 Adjustment of a herbal drug preparation to a defined range of therapeutically active constituent(s) 16 1.11.3 Adjustment of a herbal drug preparation to a fixed content of more than one therapeutically active constituent (so-called "double-adjustment").. 19

1.12 Classification of plant constituents and extracts 22 1.12.1 Constituents with known therapeutic activity (therapeutically active constituents) 22 1.12.2 Constituents which contribute to therapeutic efficacy (active constituents) 23 1.12.3 Marker substances 23 1.12.4 Standardised extracts 25 1.12.5 Quantified extracts 25 1.12.6 Other extracts 26 1.13 Refined ("purified", "enriched") extracts 26 1.14 Mixed extracts (extracts of mixtures of herbal drugs, one-pot extracts).. 27 1.15 Mixtures of herbal extracts (multiple-pot extracts) 28 2 Labelling of herbal drug preparations (extracts) 31 2.1 Adjusted (standardised) extracts (siccum extracts) 31 2.2 Quantified extracts (siccum extracts) 32 2.3 Other extracts 32 2.4 Liquid extracts (fluida) 33 2.5 Tinctures 34 2.6 Soft extracts 34 3 Quality assurance of herbal medicinal products 37 3.1 General aspects 37 3.2 Quality assurance of the herbal starting material 41 3.2.1 Identification test 44 3.2.2 Assay 44 3.2.3 Purity tests 45 3.2.4 Reference substances 45 3.3 Quality assurance of the herbal extract 46 3.3.1 Extraction solvent 48 3.3.2 Extraction procedure 48 3.3.3 Evaporation 53 3.3.4 Microbial decontamination 54 3.3.5 Drying 56 3.3.6 Filing of the specification 58 3.4 Quality assurance of the finished herbal medicinal product 59 3.4.1 Development pharmaceutics 59

3.4.2 Disintegration time 63 3.4.3 Release of herbal medicinal products 63 4 Can herbal extracts and herbal medicinal products be "essentially similar"? 67 4.1 Different approaches for the definition of phytoequivalence 68 4.2 Phytoequivalence and pharmaceutical equivalence 69 4.3 Criteria for pharmaceutical equivalence 71 4.3.1 Herbal starting material 72 4.3.2 Type and concentration of extraction solvent 72 4.3.3 Manufacturing procedure 73 4.3.4 Conformity of batches and extracts 74 4.3.5 Dosage form and dosage 75 4.4 How to establish therapeutical equivalence 76 5 The European marketing authorisation system si 5.1 Directives relating to medicinal products 81 5.2 The centralised, decentralised and national procedure 81 5.3 The option of bibliographic applications 84 5.4 Application of the decentralised procedure to herbal medicinal products 85 5.5 The Herbal Medicinal Products Working Party (HMPWP) 85 5.6 The future of marketing authorisation in the EU 88 6 Legal provisions relating to the quality of herbal drugs, herbal drug preparations and herbal medicinal products... 93 6.1 Quality, efficacy and safety as prerequisites for marketing authorisation. 93 6.2 The European Pharmacopoeia 93 6.3 Annex of Directive 2001/83/EC 94 6.3.1 Qualitative and quantitative particulars of the constituents 96 6.3.2 Development pharmaceutics 97 6.3.3 Description of the method of preparation 97 6.3.4 Control of starting materials 97 6.3.5 Control tests in intermediate stages 98 IX

6.3.6 Control tests for the finished product 98 6.3.7 Stability tests 99 6.4 The European Guidelines "Quality of herbal medicinal products" and "Specifications" 102 6.5 Other European and international guidelines 103 6.6 Tests for special impurities 104 6.6.1 Microbiological testing 104 6.6.2 Heavy metals 107 6.6.3 Aflatoxins 108 6.6.4 Plant protection products 109 6.6.5 Ethylene oxide Ill 6.6.6 Radioactivity 112 6.6.7 Residual solvents 112 6.7 Filing of the documentation: Notice to Applicants 113 6.8 Bioavailability 113 7 Legal provisions relating to efficacy and safety of herbal medicinal products 7.1 Evidence of efficacy and safety required for herbal medicinal products including the well-established medicinal use 117 7.2 Attempts to harmonise the assessment criteria 121 7.3 Special requirements for fixed combinations 124 7.4 Marketing authorisation of "traditionally used" herbal medicinal products: the national ways and future European options 124 7.5 Research in phytotherapy 129 in 8 Herbal Medicinal Products Worldwide 131 8.1 The WHO Traditional Medicine Programme 131 8.2 WHO Guidelines for the assessment of herbal medicines 131 8.3 Model monographs of widely used medicinal plants 132 8.4 Further WHO activities 132

Annex I II CPMP/CVMP Note for Guidance on Quality of Herbal Medicinal Products 135 General monographs on herbal drugs, herbal drug preparations and herbal teas (Ph. Eur., Suppl. 2000) 142 III General monograph on extracts (Ph. Eur. 2002, Suppl. 4.3) 145 IV V Monographs on herbal drugs and herbal drug preparations published in the Ph. Eur. 2002, including Suppl. 4.1 to 4.3 149 Monographs and component characteristics published by the German Commission E 151 VI Monographs published by ESCOP 1996-1999 (fascicules 1-6) 166 VII WHO Model Monographs of Widely used Medicinal Plants (including Vol. I, II and III). 170 VIII WHO Publications relating to herbal medicines 171 Index 173 XI